In patients with HCM and AF, DOAC therapy was similar to VKA therapy in reducing the risk of thromboembolic events, without increasing bleeding risk. In addition, the DOAC group displayed significant advantages in reducing mortality and intracranial hemorrhage compared with the VKA group. Further randomized controlled trials are needed to provide more evidence for DOAC therapy in this population.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- hypertrophic cardiomyopathy
- venous thromboembolism
- left atrial
- left atrial appendage
- oral anticoagulants
- catheter ablation
- left ventricular
- randomized controlled trial
- heart failure
- percutaneous coronary intervention
- stem cells
- cardiovascular events
- acute coronary syndrome
- type diabetes
- cardiovascular disease
- optic nerve
- replacement therapy